Skip Navigation


Annals of Oncology Advance Access originally published online on May 7, 2008
Annals of Oncology 2008 19(9):1639-1643; doi:10.1093/annonc/mdn178
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/9/1639    most recent
mdn178v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Heron, D. E.
Right arrow Articles by Kurman, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heron, D. E.
Right arrow Articles by Kurman, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

palliative care/quality of life

Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy

D. E. Heron1,*, A. Brufsky2, S. Beriwal1 and M. Kurman3

1 Department of Radiation Oncology
2 Division of Medical Oncology, Magee-Womens Hospital, University of Pittsburgh Cancer Institute, Pittsburgh, PA
3 Cytogen Corporation, Princeton, NJ, USA

* Correspondence to: Dr D. E. Heron, Department of Radiation Oncology, UPMC Cancer Pavilion, University of Pittsburgh Cancer Institute, 5150 Centre Avenue, Suite No. 545, Pittsburgh, PA 15232, USA. Tel: +1-412-623-6723; Fax: +1-412-647-1161; E-mail: herond2{at}upmc.edu

Background: The effect of prior treatment with radiotherapy and/or chemotherapy on the myelotoxicity of samarium lexidronam (Sm 153) in patients with metastatic bone lesions and bone pain was described.

Methods: Single-institution retrospective chart review of patients receiving Sm 153. The effect of Sm 153 on peripheral white blood cell (WBC), platelet counts, and change from baseline was calculated.

Results: The available hematologic data from records of 58 patients receiving 100 treatments with Sm 153 were reviewed. Prior treatment with radiotherapy or chemotherapy had no effect on changes from baseline or median nadir counts for either WBC or platelets when compared with patients not having such prior treatments. Multiple treatments with Sm 153 had no effect on change from baseline in WBC or platelet counts as compared with the initial administration. Median survival following the first dose of Sm 153 was 15 months.

Conclusions: Prior treatment with radiotherapy or chemotherapy did not affect the rates of myelotoxicity. Multiple treatments with samarium Sm 153 lexidronam also had no effect on severity of myelotoxicity with successive courses. Patients with bone predominant metastatic disease may survive for extended periods of time and may safely be treated with multiple modalities of therapy.

Key words: bone pain, metastasis, quadramet, radiopharmaceutical

Received for publication June 12, 2007. Revision received March 24, 2008. Accepted for publication March 31, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.